135716-08-4

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate is utilized as a building block in organic synthesis for its ability to contribute to the formation of a variety of pharmaceuticals and organic compounds. Its ethoxyketene acetal moiety acts as a versatile protecting group for aldehydes and ketones, facilitating selective chemical transformations that are crucial in the synthesis of complex organic molecules.
Used in Drug Discovery:
In the pharmaceutical industry, tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate is employed as a key intermediate in drug discovery. Its unique structure allows for the development of new drugs with potential therapeutic applications. tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate's reactivity and functional groups make it a valuable component in the design and synthesis of novel medicinal agents.
Further research and experimentation are essential to fully understand the properties and applications of tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate, ensuring its optimal use in these fields.

InChI:InChI=1S/C14H23NO4/c1-5-18-12(16)10-11-6-8-15(9-7-11)13(17)19-14(2,3)4/h10H,5-9H2,1-4H3

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 41661-47-6 piperidin-4-one 
• 10419-80-4 O,O-diethyl ethoxymethylphosphonate 
• 311-46-6 ethyl 2-(dimethoxyphosphoryl)acetate 
• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 40110-55-2 ethyl 2-(1-benzylpiperidine-4-ylidene)acetate 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 301221-63-6 tert-butyl 4-(1-bromo-2-oxoethyl)piperidine-1-carboxylate 
• 301221-19-2 tert-butyl 4-(imidazo[1,2-a]pyridin-3-yl)piperidine-1-carboxylate 
• 1032825-55-0 tert-butyl 4-(1-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate 
• 1381841-47-9 C₂₀H₂₂ClN₃ 
• 1381841-45-7 C₂₀H₂₀ClN₃ 
• 151238-69-6 C₂₀H₂₀FN₃ 
• 1259040-11-3 C₃₂H₄₇N₇O₂ 
• 1259040-09-9 C₂₃H₃₆N₂O₂ 
• 1259040-08-8 C₁₈H₂₆N₂O₂ 
• 1259040-06-6 2-(4-{[bis(1H-imidazol-2-ylmethyl)amino]methyl}benzyl)-8-(1-ethylpropyl)-2,8-diazaspiro[4.5]decane-4-carboxylic acid 
• 1259040-07-7 8-(tert-butyl) 4-ethyl 2-benzyl-2,8-diazaspiro[4.5]decane-4,8-dicarboxylate 
• 1365135-32-5 3-[(2-Chloro-benzoyl)amino]-N-[2-(1-pyridin-4-yl-piperidin-4-yl)-ethyl]-2,3-dihydro-1H-indene-5-carboxylic acid amide 
• 1365155-56-1 N-Benzyl-N-methyl-2-(1-(pyridin-4-yl)piperidin-4-yl)ethanamine 

Relevant academic research and scientific papers

Substituted furo[3,2-b]pyridines: Novel bioisosteres of 5-HT1F receptor agonists

Synthesis and evaluation of a series of 2,3,5- and 3,5-substituted furo[3,2-b]pyridines were undertaken in order to investigate their utility as bioisosteres of 5-HT1F receptor agonist indole analogues, 1-3. The replacement proved to be effective, providing compounds with similar 5-HT 1F receptor affinity and improved selectivity when compared with the indole analogues. Through these studies we identified 4-fluoro-N-[3-(1-methyl- piperidin-4-yl)-furo[3,2-b]pyridin-5-yl]-benzamide (5), a potent and selective 5-HT1F receptor agonist with the potential to treat acute migraine.

HERBICIDAL COMPOUNDS

The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3,W, Y, Z and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling weeds, in particular in crops of useful plants.

Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-b]indole Derivatives against Gram-Negative Multidrug-Resistant Pathogens

Due to the poor permeability across Gram-negative bacterial membranes and the troublesome bacterial efflux mechanism, only a few GyrB/ParE inhibitors with potent activity against Gram-negative pathogens have been reported. Among them, pyrimido[4,5-b]indol

Cobalt-Catalyzed Diastereo- And Enantioselective Reductive Allyl Additions to Aldehydes with Allylic Alcohol Derivatives via Allyl Radical Intermediates

Catalytic generation of ambiphilic π-allyl-metal complexes and their utility in enantioselective transformations constitutes a powerful approach for introduction of allyl groups to a molecule. Herein an unprecedented cobalt-catalyzed highly site-, diastereo-, and enantioselective protocol for stereoselective formation of nucleophilic allyl-Co(II) complexes followed by addition to aldehydes is presented. The reaction features diastereo- and enantioconvergent conversion of easily accessible allylic alcohol derivatives to diversified enantioenriched homoallylic alcohols with a remarkably broad scope of allyl groups that can be introduced. Mechanistic studies indicated that allyl radical intermediates were involved in this process. These new discoveries establish a new strategy for development of enantioselective transformations through capture of radicals by chiral Co complexes, pushing forward the frontier of Co complexes for enantioselective catalysis.

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

5-ARYL-3,9-DIAZASPIRO[5.5]UNDECAN-2-ONE COMPOUNDS

The present invention covers 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (l-a): in which A, R1 and R2 are as defined herein, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, and compounds of general formula (l-c) and general formula (l-d): in which R1 and R2 are as defined herein, for the treatment and/or prophylaxis of diseases, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions.

5-ARYL-3,9-DIAZASPIRO[5.5]UNDECAN-2-ONE COMPOUNDS

The present invention covers 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds of general formula (I) and general formula (I-a): (I) and (I-a), in which R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

Visible-Light-Promoted Intramolecular α-Allylation of Aldehydes in the Absence of Sacrificial Hydrogen Acceptors

We report herein an unprecedented protocol for radical cyclization of aldehydes with pendant alkenes via synergistic photoredox, cobaloxime, and amine catalysis. The transformation was achieved in the absence of external oxidants, providing a variety of 5-, 6-, and 7-membered ring products with alkene transposition in satisfactory yields. The reaction exhibits wide functional group compatibility and occurs under mild conditions with extrusion of H2.

SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

The present disclosure relates to compounds of formula (I) that are useful as modulators of 7α nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery

In recent years the pharmaceutical industry has benefited from the advances made in fragment-based drug discovery (FBDD) with more than 30 fragment-derived drugs currently marketed or progressing through clinical trials. The success of fragment-based drug